Eribulin Mesylate Injection
NDC 68083-592
Product Information
Eribulin Mesylate is a ANDA-approved product labeled by Gland Pharma Limited. Eribulin is used to treat certain types of cancer (breast, liposarcoma). It is supplied as a injection for intravenous administration. This product entry covers the primary NDC 68083-592 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 68083-592?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ERIBULIN MESYLATE (UNII: AV9U0660CW)
- ERIBULIN (UNII: LR24G6354G) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ALCOHOL (UNII: 3K9958V90M)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1045456 - eriBULin mesylate 1 MG in 2 ML Injection
- RxCUI: 1045456 - 2 ML eribulin mesylate 0.5 MG/ML Injection
- RxCUI: 1045456 - eribulin mesylate 1 MG per 2 ML Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.